Abstract
Introduction
Nebivolol, a highly selective β1-adrenergic receptor-blocker, increases basal and stimulated endothelial nitric oxide (NO)-release. It is unknown, whether coronary perfusion is improved by the increase in NO availability. Therefore, we sought to evaluate the effect of nebivolol on coronary flow reserve (CFR) and collateral flow.
Methods
Doppler-flow wire derived coronary flow velocity measurements were obtained in ten controls and eight patients with coronary artery disease (CAD) at rest and after intracoronary nebivolol. CFR was defined as maximal flow during adenosine-induced hyperemia divided by resting flow. In the CAD group, collateral flow was determined after dilatation of a flow-limiting coronary stenosis. Collateral flow index (CFI) was defined as the ratio of flow velocity during balloon inflation divided by resting flow.
Results
CFR at rest was 3.0 ± 0.6 in controls and 2.1 ± 0.4 in CAD patients. After intracoronary doses of 0.1, 0.25, and 0.5 mg nebivolol, CFR increased to 3.4 ± 0.7, 3.9 ± 0.9, and 4.0 ± 0.1 (p < 0.01) in controls, and to 2.3 ± 0.7, 2.6 ± 0.9, and 2.6 ± 0.5 (p < 0.05) in CAD patients. CFI decreased significantly with intracoronary nebivolol and correlated to changes in heart rate (r = 0.75, p < 0.001) and rate-pressure product (r = 0.59, p = 0.001).
Discussion
Intracoronary nebivolol is associated with a significant increase in CFR due to reduction in resting flow (controls), or due to an increase in maximal coronary flow (CAD patients). CFI decreased with nebivolol parallel to the reduction in myocardial oxygen consumption.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Hilton R, Eicholtz F. The influence of chemical factors on the coronary circulation. J Physiol 1925;59:413–25.
Katz LN, Lindner E. Quantitative relation between reactive hyperemia and the myocardial ischemia which it follows. Am J Physiol 1939;126:283–8.
Coffman JD, Gregg DE. Reactive hyperemia characteristics of the myocardium. Am J Physiol 1960;199:1143–9.
Marcus M, Wright C, Doty D, Eastham C, Laughlin D, Krumm P, et al. Measurements of coronary velocity and reactive hyperemia in the coronary circulation of humans. Circ Res 1981;49(4):877–91.
Bookstein JJ, Higgins CB. Comparative efficacy of coronary vasodilatory methods. Invest Radiol 1977;12(2):121–7.
Christensen CW, Rosen LB, Gal RA, Haseeb M, Lassar TA, Port SC. Coronary vasodilator reserve. Comparison of the effects of papaverine and adenosine on coronary flow, ventricular function, and myocardial metabolism. Circulation 1991;83(1):294–303.
Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD. Effects of adenosine on human coronary arterial circulation. Circulation 1990;82(5):1595–606.
Rossen JD, Quillen JE, Lopez AG, Stenberg RG, Talman CL, Winniford MD. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine. J Am Coll Cardiol 1991;18(2):485–91.
Felder L, Vassalli G, Vassalli F, Jiang Z, Grimm J, Krayenbuehl HP, et al. Clinical significance of coronary flow reserve: effect of papaverine and exercise. Coron Artery Dis 1994;5(4):347–58.
Marcus ML, Chilian WM, Kanatsuka H, Dellsperger KC, Eastham CL, Lamping KG. Understanding the coronary circulation through studies at the microvascular level. Circulation 1990;82(1):1–7.
Bottcher M, Czernin J, Sun K, Phelps ME, Schelbert HR. Effect of beta 1 adrenergic receptor blockade on myocardial blood flow and vasodilatory capacity. J Nucl Med 1997;38(3):442–6.
Billinger M, Seiler C, Fleisch M, Eberli FR, Meier B, Hess OM. Do beta-adrenergic blocking agents increase coronary flow reserve? J Am Coll Cardiol 2001;38(7):1866–71.
Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 2004;110(8):948–54.
Doucette JW, Corl PD, Payne HM, Flynn AE, Goto M, Nassi M, et al. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation 1992;85(5):1899–911.
Dawes M, Brett SE, Chowienczyk PJ, Mant TG, Ritter JM. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999;48(3):460–3.
Young MA, Vatner DE, Vatner SF. Alpha- and beta-adrenergic control of large coronary arteries in conscious calves. Basic Res Cardiol 1990;85(Suppl 1):97–109.
Robertson RM, Wood AJ, Vaughn WK, Robertson D. Exacerbation of vasotonic angina pectoris by propranolol. Circulation 1982;65(2):281–5.
Kern MJ, Ganz P, Horowitz JD, Gaspar J, Barry WH, Lorell BH, et al. Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease. Circulation 1983;67(6):1178–85.
Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frerart F, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005;112(8):1198–205.
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26(3):215–25.
Stoleru L, Wijns W, van Eyll C, Bouvy T, Van Nueten L, Pouleur H. Effects of d-nebivolol and l-nebivolol on left ventricular systolic and diastolic function: comparison with d-l-nebivolol and atenolol. J Cardiovasc Pharmacol 1993;22(2):183–90.
Galderisi M, Cicala S, D’Errico A, de Divitiis O, de Simone G. Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease. J Hypertens 2004;22(11):2201–8.
Lekakis JP, Protogerou A, Papamichael C, Vamvakou G, Iconomidis I, Fici F, et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther 2005;19(4):277–81.
Billinger M, Raeber L, Seiler C, Windecker S, Meier B, Hess OM. Coronary collateral perfusion in patients with coronary artery disease: effect of metoprolol. Eur Heart J 2004;25(7):565–70.
Acknowledgements
Dr Francesco Vigorito was supported by an educational grant of Menarini S.A., Firenze, Italy.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Togni, M., Vigorito, F., Windecker, S. et al. Does the β-Blocker Nebivolol Increase Coronary Flow Reserve?. Cardiovasc Drugs Ther 21, 99–108 (2007). https://doi.org/10.1007/s10557-006-0494-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-006-0494-7